← All trials
NCT04701918
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 4, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Jan 8, 2021
- Last posted
- Oct 29, 2021
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Biocompatibles International plcCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.